See more : Ophir Gold Corp. (KPZIF) Income Statement Analysis – Financial Results
Complete financial analysis of Teleflex Incorporated (TFX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Teleflex Incorporated, a leading company in the Medical – Instruments & Supplies industry within the Healthcare sector.
You may be interested
- Kahan Packaging Limited (KAHAN.BO) Income Statement Analysis – Financial Results
- Creo Co.,Ltd. (9698.T) Income Statement Analysis – Financial Results
- WHA Utilities and Power Public Company Limited (WHAUP.BK) Income Statement Analysis – Financial Results
- Coca-Cola Co (COLA.NE) Income Statement Analysis – Financial Results
- Artemis Gold Inc. (ARGTF) Income Statement Analysis – Financial Results
Teleflex Incorporated (TFX)
About Teleflex Incorporated
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site. The company also offers interventional products, which consists of various coronary catheters, structural heart therapies, and peripheral intervention and cardiac assist products that are used by interventional cardiologists and radiologists, and vascular surgeons; and Arrow branded catheters, Guideline and Trapliner catheters, the Manta Vascular Closure, and Arrow Oncontrol devices. It provides anesthesia products, such as airway and pain management products to support hospital, emergency medicine, and military channels; and surgical products, including metal and polymer ligation clips, and fascial closure surgical systems that are used in laparoscopic surgical procedures, percutaneous surgical systems, and other surgical instruments. The company also offers interventional urology products comprising the UroLift System, an invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia; and respiratory products, including oxygen and aerosol therapies, spirometry, and ventilation management products for use in various care settings. It provides urology products, such as catheters, urine collectors, and catheterization accessories and products for operative endourology; and bladder management services. The company serves hospitals and healthcare providers, medical device manufacturers, and home care markets. The company was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 | 1986 | 1985 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.97B | 2.79B | 2.81B | 2.54B | 2.60B | 2.45B | 2.15B | 1.87B | 1.81B | 1.84B | 1.70B | 1.55B | 1.53B | 1.80B | 1.89B | 2.42B | 1.93B | 2.65B | 2.51B | 2.49B | 2.28B | 2.08B | 1.91B | 1.76B | 1.60B | 1.44B | 1.15B | 931.20M | 912.70M | 812.70M | 666.80M | 567.10M | 479.50M | 441.10M | 355.60M | 328.20M | 269.80M | 214.20M | 171.80M |
| Cost of Revenue | 1.33B | 1.26B | 1.26B | 1.21B | 1.10B | 1.06B | 974.50M | 871.83M | 865.29M | 897.40M | 857.33M | 802.78M | 810.07M | 1.01B | 1.08B | 1.46B | 1.25B | 1.87B | 1.80B | 1.79B | 1.68B | 1.52B | 1.37B | 1.20B | 1.09B | 969.60M | 746.90M | 601.40M | 590.30M | 524.40M | 431.00M | 360.40M | 311.80M | 286.90M | 237.20M | 215.50M | 175.80M | 140.50M | 114.70M |
| Gross Profit | 1.65B | 1.53B | 1.55B | 1.32B | 1.49B | 1.38B | 1.17B | 996.20M | 944.40M | 942.43M | 838.95M | 748.23M | 718.84M | 794.07M | 814.08M | 964.17M | 680.35M | 774.19M | 709.95M | 698.80M | 597.79M | 552.45M | 535.29M | 567.70M | 512.60M | 468.00M | 398.90M | 329.80M | 322.40M | 288.30M | 235.80M | 206.70M | 167.70M | 154.20M | 118.40M | 112.70M | 94.00M | 73.70M | 57.10M |
| Gross Profit Ratio | 55.37% | 54.86% | 55.15% | 52.22% | 57.47% | 56.55% | 54.60% | 53.33% | 52.19% | 51.22% | 49.46% | 48.24% | 47.02% | 44.07% | 43.07% | 39.83% | 35.17% | 29.25% | 28.23% | 28.12% | 26.19% | 26.61% | 28.10% | 32.17% | 32.02% | 32.55% | 34.81% | 35.42% | 35.32% | 35.47% | 35.36% | 36.45% | 34.97% | 34.96% | 33.30% | 34.34% | 34.84% | 34.41% | 33.24% |
| Research & Development | 154.35M | 153.82M | 130.84M | 119.75M | 113.86M | 106.21M | 84.77M | 58.58M | 52.12M | 61.04M | 65.05M | 56.28M | 48.73M | 42.62M | 0.00 | 0.00 | 30.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 991.05M | 863.75M | 860.09M | 743.57M | 934.37M | 878.69M | 699.96M | 563.31M | 568.98M | 578.66M | 502.19M | 454.49M | 429.26M | 475.32M | 519.93M | 596.77M | 445.25M | 493.52M | 449.04M | 494.43M | 423.03M | 365.02M | 347.13M | 311.28M | 284.70M | 266.10M | 230.20M | 190.30M | 192.40M | 173.90M | 141.00M | 124.20M | 93.70M | 84.80M | 63.90M | 59.10M | 49.60M | 39.80M | 31.70M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 582.00K | -341.00K | 2.60M | 2.34M | 0.00 | 838.00K | -14.22M | -2.73M | -1.93B | -18.90M | 0.00 | 77.42M | 67.40M | 60.10M | 47.90M | 38.80M | 37.70M | 33.00M | 28.10M | 21.60M | 18.40M | 17.20M | 12.90M | 11.00M | 9.80M | 7.20M | 4.80M |
| Operating Expenses | 1.14B | 1.02B | 990.93M | 863.32M | 1.05B | 984.90M | 784.73M | 621.89M | 621.10M | 639.70M | 567.23M | 510.77M | 478.58M | 517.60M | 522.52M | 624.18M | 445.25M | 494.35M | 434.82M | 491.70M | -1.51B | 346.12M | 347.13M | 388.70M | 352.10M | 326.20M | 278.10M | 229.10M | 230.10M | 206.90M | 169.10M | 145.80M | 112.10M | 102.00M | 76.80M | 70.10M | 59.40M | 47.00M | 36.50M |
| Cost & Expenses | 2.47B | 2.28B | 2.25B | 2.08B | 2.15B | 2.05B | 1.76B | 1.49B | 1.49B | 1.54B | 1.42B | 1.31B | 1.29B | 1.53B | 1.60B | 2.08B | 1.70B | 2.37B | 2.24B | 2.28B | 177.83M | 1.87B | 1.72B | 1.59B | 1.44B | 1.30B | 1.03B | 830.50M | 820.40M | 731.30M | 600.10M | 506.20M | 423.90M | 388.90M | 314.00M | 285.60M | 235.20M | 187.50M | 151.20M |
| Interest Income | 12.78M | 912.00K | 1.33M | 1.16M | 1.74M | 944.00K | 771.00K | 474.00K | 532.00K | 706.00K | 624.00K | 1.57M | 1.26M | 861.00K | 2.54M | 2.64M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 85.08M | 54.26M | 56.97M | 66.49M | 80.27M | 103.02M | 82.55M | 54.94M | 61.32M | 65.46M | 56.91M | 69.57M | 70.32M | 80.03M | 89.46M | 121.65M | 0.00 | 0.00 | 0.00 | 37.12M | 26.34M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 242.12M | 230.59M | 237.36M | 227.25M | 214.06M | 209.98M | 155.26M | 117.91M | 108.39M | 111.13M | 92.98M | 80.47M | 85.62M | 92.19M | 101.06M | 111.22M | 78.76M | 99.00M | 100.85M | 114.60M | 104.35M | 95.12M | 92.40M | 77.42M | 67.40M | 60.10M | 47.90M | 38.80M | 37.70M | 33.00M | 28.10M | 21.60M | 18.40M | 17.20M | 12.90M | 11.00M | 9.80M | 7.20M | 4.80M |
| EBITDA | 761.21M | 751.65M | 873.10M | 665.98M | 634.24M | 532.63M | 522.72M | 418.57M | 414.36M | 396.70M | 325.61M | -26.39M | 288.87M | 302.71M | 353.78M | 453.84M | 313.86M | 309.20M | 284.14M | 308.41M | 302.80M | 307.27M | 280.56M | 256.42M | 227.90M | 201.90M | 168.70M | 139.50M | 130.00M | 114.40M | 94.80M | 82.50M | 74.00M | 69.40M | 54.50M | 53.60M | 44.40M | 33.90M | 25.40M |
| EBITDA Ratio | 25.59% | 26.69% | 28.38% | 27.19% | 25.40% | 24.93% | 25.30% | 26.38% | 23.88% | 22.53% | 21.54% | 20.60% | 15.80% | 20.51% | 20.91% | 18.75% | 19.40% | 15.30% | 15.46% | 15.55% | 96.65% | 14.03% | 14.73% | 14.53% | 14.23% | 14.04% | 14.72% | 14.98% | 14.24% | 14.08% | 14.22% | 13.98% | 14.70% | 15.03% | 14.09% | 16.33% | 15.72% | 13.96% | 12.92% |
| Operating Income | 506.31M | 499.73M | 628.10M | 423.07M | 427.25M | 321.70M | 372.28M | 319.45M | 315.89M | 284.86M | 233.26M | -97.38M | 233.17M | 273.59M | 269.77M | 339.99M | 192.64M | 254.61M | 248.07M | 139.49M | 2.10B | 206.33M | 188.16M | 179.00M | 160.50M | 141.80M | 120.80M | 100.70M | 92.30M | 81.40M | 66.70M | 60.90M | 55.60M | 52.20M | 41.60M | 42.60M | 34.60M | 26.70M | 20.60M |
| Operating Income Ratio | 17.02% | 17.90% | 22.36% | 16.67% | 16.46% | 13.14% | 17.35% | 17.10% | 17.46% | 15.48% | 13.75% | -6.28% | 15.25% | 15.19% | 14.27% | 14.04% | 9.96% | 9.62% | 9.87% | 5.61% | 92.21% | 9.94% | 9.88% | 10.14% | 10.02% | 9.86% | 10.54% | 10.81% | 10.11% | 10.02% | 10.00% | 10.74% | 11.60% | 11.83% | 11.70% | 12.98% | 12.82% | 12.46% | 11.99% |
| Total Other Income/Expenses | -72.30M | -53.81M | -68.63M | -65.34M | -122.08M | 23.20M | -87.37M | -73.73M | -71.25M | -64.75M | -57.53M | -181.78M | -84.47M | -82.50M | -86.92M | -119.01M | -83.29M | -35.93M | -39.67M | -42.35M | -23.27M | -33.84M | -28.47M | -20.79M | -17.77M | -16.98M | -14.40M | -13.90M | -18.70M | -18.40M | -14.40M | -12.30M | -10.30M | -9.30M | -2.40M | -6.20M | -2.90M | 200.00K | 1.60M |
| Income Before Tax | 434.01M | 445.92M | 559.47M | 357.73M | 339.90M | 219.63M | 284.91M | 245.73M | 244.65M | 220.11M | 175.73M | -165.37M | 148.70M | 147.79M | 182.85M | 220.98M | 109.35M | 219.03M | 207.92M | 102.37M | 151.49M | 172.49M | 159.70M | 158.21M | 142.70M | 124.80M | 106.40M | 86.80M | 73.60M | 63.00M | 52.30M | 48.60M | 45.30M | 42.90M | 39.20M | 36.40M | 31.70M | 26.90M | 22.20M |
| Income Before Tax Ratio | 14.59% | 15.98% | 19.91% | 14.10% | 13.10% | 8.97% | 13.27% | 13.15% | 13.52% | 11.96% | 10.36% | -10.66% | 9.73% | 8.20% | 9.67% | 9.13% | 5.65% | 8.28% | 8.27% | 4.12% | 6.64% | 8.31% | 8.38% | 8.97% | 8.91% | 8.68% | 9.29% | 9.32% | 8.06% | 7.75% | 7.84% | 8.57% | 9.45% | 9.73% | 11.02% | 11.09% | 11.75% | 12.56% | 12.92% |
| Income Tax Expense | 76.44M | 83.00M | 74.35M | 21.93M | -122.08M | 23.20M | 129.65M | 8.07M | 7.84M | 28.65M | 23.55M | 16.41M | 27.00M | 21.89M | 39.90M | 52.17M | 122.77M | 54.14M | 47.81M | 14.35M | 42.39M | 47.22M | 47.38M | 48.99M | 47.50M | 42.20M | 36.30M | 29.60M | 24.70M | 21.80M | 18.60M | 16.60M | 15.50M | 14.30M | 12.40M | 12.40M | 12.00M | 10.50M | 8.90M |
| Net Income | 356.33M | 363.14M | 485.37M | 335.32M | 461.47M | 200.80M | 152.53M | 237.38M | 244.86M | 187.68M | 150.88M | -190.06M | 323.33M | 201.09M | 302.99M | 119.77M | 146.48M | 139.43M | 138.82M | 9.52M | 109.10M | 125.27M | 112.31M | 109.22M | 95.20M | 82.60M | 70.10M | 57.20M | 48.90M | 41.20M | 33.70M | 32.90M | 29.80M | 28.60M | 26.80M | 24.00M | 19.70M | 16.40M | 13.30M |
| Net Income Ratio | 11.98% | 13.01% | 17.28% | 13.22% | 17.78% | 8.20% | 7.11% | 12.71% | 13.53% | 10.20% | 8.89% | -12.25% | 21.15% | 11.16% | 16.03% | 4.95% | 7.57% | 5.27% | 5.52% | 0.38% | 4.78% | 6.03% | 5.90% | 6.19% | 5.95% | 5.75% | 6.12% | 6.14% | 5.36% | 5.07% | 5.05% | 5.80% | 6.21% | 6.48% | 7.54% | 7.31% | 7.30% | 7.66% | 7.74% |
| EPS | 7.58 | 7.74 | 10.38 | 7.21 | 9.99 | 4.39 | 3.39 | 5.48 | 5.89 | 4.54 | 3.67 | -4.65 | 7.98 | 5.04 | 7.63 | 3.03 | 3.73 | 3.51 | 3.43 | 0.24 | 2.76 | 3.12 | 2.90 | 2.86 | 2.52 | 2.21 | 1.91 | 1.58 | 1.38 | 1.18 | 0.98 | 0.97 | 0.89 | 0.87 | 0.82 | 0.74 | 0.60 | 0.51 | 0.42 |
| EPS Diluted | 7.53 | 7.68 | 10.23 | 7.09 | 9.80 | 4.29 | 3.27 | 4.98 | 5.10 | 4.04 | 3.45 | -4.65 | 7.92 | 4.99 | 7.59 | 3.01 | 3.73 | 3.49 | 3.39 | 0.24 | 2.73 | 3.08 | 2.86 | 2.83 | 2.47 | 2.15 | 1.86 | 1.58 | 1.38 | 1.18 | 0.98 | 0.97 | 0.89 | 0.87 | 0.82 | 0.74 | 0.60 | 0.51 | 0.42 |
| Weighted Avg Shares Out | 46.98M | 46.90M | 46.77M | 46.49M | 46.20M | 45.69M | 45.00M | 43.33M | 41.56M | 41.37M | 41.11M | 40.86M | 40.50M | 39.91M | 39.72M | 39.58M | 39.26M | 39.76M | 40.52M | 40.21M | 39.60M | 40.15M | 38.73M | 38.19M | 37.78M | 37.38M | 36.70M | 36.20M | 35.56M | 35.06M | 34.39M | 33.92M | 33.48M | 32.87M | 32.68M | 32.43M | 32.83M | 32.16M | 31.67M |
| Weighted Avg Shares Out (Dil) | 47.30M | 47.31M | 47.43M | 47.29M | 47.09M | 46.80M | 46.66M | 47.65M | 48.06M | 46.47M | 43.69M | 40.86M | 40.80M | 40.28M | 39.94M | 39.83M | 39.26M | 39.99M | 40.96M | 40.50M | 39.94M | 40.67M | 39.27M | 38.60M | 38.54M | 38.42M | 37.69M | 36.20M | 35.56M | 35.06M | 34.39M | 33.92M | 33.48M | 32.87M | 32.68M | 32.43M | 32.83M | 32.16M | 31.67M |
Teleflex Announces the Limited Market Release of the Wattson™ Temporary Pacing Guidewire
Company expands structural heart portfolio and begins the limited market release of a bipolar temporary pacing guidewire intended to introduce and position catheters and other interventional devices within the chambers of the heart while transmitting an electrical signal from an...
Teleflex to Present at the BofA Securities 2024 Health Care Conference
WAYNE, Pa., April 30, 2024 (GLOBE NEWSWIRE) -- Liam Kelly, Chairman, President and CEO, Teleflex Incorporated (NYSE: TFX), is scheduled to speak at the BofA Securities 2024 Health Care Conference at the Encore Hotel in Las Vegas, Nevada, on Tuesday,...
Teleflex Announces First Quarter 2024 Earnings Conference Call Information
WAYNE, Pa., April 18, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its first quarter financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, May 2, 2024.
Teleflex (TFX) Debuts the New Unified UroLift 2 System With ATC
Teleflex's (TFX) new UroLift 2 System with the ATC platform is designed to treat all prostate types.
Teleflex Incorporated Introduces the UroLift™ 2 System With Advanced Tissue Control, a Revolutionary Unified Platform Designed to Treat All Prostate Types
WAYNE, Pa., April 02, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced the upcoming full market release of the Advanced Tissue Control (ATC) feature on its unified UroLift™ 2 System platform designed...
Teleflex's Climate Targets Validated by the Science Based Targets Initiative
Teleflex commits to reach net-zero greenhouse gas emissions across its value chain by 2050. Teleflex commits to reach net-zero greenhouse gas emissions across its value chain by 2050.
Glancy Prongay & Murray LLP Announces Investigation of Teleflex Incorporated (TFX)
NEW YORK--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) announces its investigation of Teleflex Incorporated (NYSE: TFX) concerning the Company and its directors' and officers' possible violations of state laws. If you own Teleflex stock, would like to learn more about...
Here's Why You Should Retain Teleflex (TFX) Stock for Now
Investors are optimistic about Teleflex (TFX) on robust growth in the Vascular business and strong Urolift prospects.
Teleflex (TFX) Q4 Earnings Top Estimates, Operating Margin Falls
Teleflex (TFX) surpasses earnings and revenue estimates in the fourth quarter of 2023.
Compared to Estimates, Teleflex (TFX) Q4 Earnings: A Look at Key Metrics
Although the revenue and EPS for Teleflex (TFX) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Source: https://incomestatements.info
Category: Stock Reports